🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

MitrAl Valve Calcium aSsEssmEnt With TrueVue Trans-illumination 3D Rendering.

Recruitingn/aAges 18 Years - anyAllCentro Cardiologico Monzino
NCT07612553 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The study of calcifications involving the mitral valve is extremely important for the planning of both surgical and percutaneous procedures. Computed tomography (CT) is the non-invasive imaging modality considered the gold standard for the assessment of mitral valve calcifications, thanks to its high spatial resolution and the strong X-ray attenuation of calcium deposits. Echocardiography has traditionally played a limited role in the evaluation of mitral valve calcifications, particularly with three-dimensional imaging. Three-dimensional transesophageal echocardiographic rendering with TrueVue transillumination (Philips Medical Systems, Eindhoven, NL) can provide additional information on the location and extent of calcium on the mitral valve by allowing the placement of a virtual light source beneath the mitral valve. Specifically, the TrueVue system is an advanced software module in

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria Retrospective Cohort * Have already undergone, between February 2025 and September 2025, a contrast-enhanced CT scan and a transesophageal echocardiogram. * Are ≥ 18 years old. Prospective Cohort * Are scheduled to undergo a contrast-enhanced CT scan and a three-dimensional transesophageal echocardiogram as part of their routine clinical assessment for their underlying cardiac condition, with or without mitral annular or leaflet calcifications. * Are ≥ 18 years old * who have provided written informed consent to participate in the study Exclusion Criteria: Retrospective Cohort * The following patients will be considered not eligible: * Patients younger than 18 years. * Patients whose data are incomplete for the purposes of the planned study assessments * Patients who have explicitly refused the use of their data for research purposes. Prospective Cohort * Patients younger than 18 years. * Patients who have not signed the study Informed Consent Form
💊

What it tests

  • Not listed
📍

Where

1 site
Centro Cardiologico Monzino; IRCCS
Milan, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy